RapidFire is in-line solid phase extraction technology which enables ultrafast, direct analysis of native compounds for a variety of biochemical assays.
The Hamburg facility will be equipped with the technology from Agilent together with multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.
Evotec chief operating officer Mario Polywka said, "Working with Agilent will ensure that these systems are brought into operation quickly and that our partners and collaborators will benefit from further efficiencies in lead discovery."
Agilent Biological Systems Division vice president and general manager Gustavo Salem said, "Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard Mass Spectrometry platforms."